
Kazia Therapeutics Limited KZIA
$ 7.62
-11.25%
Annual report 2022
added 10-17-2022
Kazia Therapeutics Limited Gross Profit 2011-2025 | KZIA
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Kazia Therapeutics Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 89 K | 87 K | 1.11 M | 1.51 M | 2.02 M |
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.02 M | 87 K | 965 K |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-40.6 M | $ 4.75 | 1.5 % | $ 788 M | ||
|
Aclaris Therapeutics
ACRS
|
172 K | $ 3.05 | 5.17 % | $ 236 M | ||
|
Aptevo Therapeutics
APVO
|
4.31 M | $ 0.93 | -8.99 % | $ 257 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
Ascendis Pharma A/S
ASND
|
319 M | $ 211.85 | 1.25 % | $ 5 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
Alterity Therapeutics Limited
ATHE
|
177 K | $ 3.14 | 1.62 % | $ 7.55 B | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
1.12 M | - | -15.15 % | $ 60.3 M | ||
|
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
374 M | $ 26.96 | 1.93 % | $ 1.31 B | ||
|
Anika Therapeutics
ANIK
|
103 M | $ 9.5 | 1.17 % | $ 139 M | ||
|
Catalyst Biosciences
CBIO
|
109 M | $ 12.5 | 3.14 % | $ 823 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 0.17 | -29.21 % | $ 370 M | ||
|
Arena Pharmaceuticals
ARNA
|
319 K | - | -6.81 % | $ 3.04 B | ||
|
Athersys
ATHX
|
1.44 M | - | 3.77 % | $ 22.4 M | ||
|
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | ||
|
Axon Enterprise
AXON
|
1.24 B | $ 587.53 | -0.59 % | $ 44.5 B | ||
|
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
45.8 M | $ 2.49 | -2.06 % | $ 15.6 M | ||
|
AstraZeneca PLC
AZN
|
43.9 B | $ 92.36 | 0.24 % | $ 96.9 B | ||
|
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
1.82 K | - | -5.38 % | $ 6.06 M | ||
|
Celldex Therapeutics
CLDX
|
5.48 M | $ 26.72 | 0.53 % | $ 1.72 M | ||
|
BeiGene, Ltd.
BGNE
|
3.22 B | - | 0.49 % | $ 251 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
371 M | $ 10.7 | 1.61 % | $ 692 M | ||
|
Biogen
BIIB
|
12.4 B | $ 176.56 | 0.99 % | $ 25.7 B | ||
|
Abeona Therapeutics
ABEO
|
925 K | $ 5.46 | 3.02 % | $ 117 M | ||
|
ADiTx Therapeutics
ADTX
|
-493 K | $ 1.17 | -7.52 % | $ 15.4 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
500 | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
53.8 M | - | -7.31 % | $ 87 M | ||
|
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
301 M | $ 84.39 | 2.93 % | $ 8.71 B | ||
|
Завод ДИОД
DIOD
|
325 M | - | - | - |